ChromaDex banner

Danny Sullivan

About

Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
163 POSTS

/

0 COMMENTS

Articles

“Adjust the immune system… de-age the brain”

Stanford study finds that blocking certain interactions on immune cells reverses age-related mental decline in older mice. Stanford University researchers have published a new study...

Senolytic start-up gears up for clinical trials

Rubedo’s first target is respiratory disease, with COVID-19 expected to drive an increase in lung disease over the next 10 years.   Late last year,...

Gerostate Alpha: “Our phenotype is lifespan”

Buck Institute start-up's founders talk drug discovery, indications and raising funding. Following yesterday's introduction to Gerostate Alpha, today we continue our interview with two of...

“The major modulators of aging remain to be discovered”

Buck Institute start-up Gerostate Alpha reveals work to develop small molecule drugs that simultaneously target multiple pathways of aging. Deep in the labs of the...

New Longevity supplement targets cognitive decline

Clinical trial planned for Mitocholine, which targets the “brain energy gap” to counteract development of metabolic syndrome and impede the onset of dementia. A London-based...

InsideTracker: personalised potential for a longer life

If you want accurate data to start, and then track, your healthspan/lifespan interventions – InsideTracker could be just what you're looking for. US startup InsideTracker...

R42 launches $14 million Longevity fund

We speak exclusively to Ronjon Nag about his first fund, targeting seed investments in Longevity AI and biotech. The world of Longevity-specific investment funds just...

Clene goes for gold, and goes public

Company targeting neurodegenerative disease with gold nanocatalyst technology goes public; multiple human trials ongoing for MS, Parkinson's and ALS. Salt Lake City biopharma company Clene...

A year in Longevity: founders’ perspectives

Speaking to the innovators behind some of Longevity’s most exciting companies. Continuing our look back at some of the highlights of 2020, we thought we’d...